Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients.

[1]  David M. Fram,et al.  Association Between Implementation of the Severe Sepsis and Septic Shock Early Management Bundle Performance Measure and Outcomes in Patients With Suspected Sepsis in US Hospitals , 2021, JAMA network open.

[2]  C. Coopersmith,et al.  Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021 , 2021, Critical care medicine.

[3]  J. Bischof,et al.  Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care. , 2021, The American journal of emergency medicine.

[4]  Chien‐Hua Huang,et al.  Factors associated with a high-risk return visit to the emergency department: a case-crossover study , 2021, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[5]  J. Morse,et al.  Nurse-Delivered Telephone Intervention to Reduce Oral Mucositis and Prevent Dehydration. , 2021, Oncology nursing forum.

[6]  F. Babl,et al.  Managing low‐risk febrile neutropenia in children in the time of COVID‐19: What matters to parents and clinicians , 2021, Journal of paediatrics and child health.

[7]  T. Cooksley,et al.  Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper , 2020, Supportive Care in Cancer.

[8]  T. Yiğenoğlu,et al.  Evaluation of Risk Factors for Mortality in Febrile Neutropenia. , 2020, Journal of infection in developing countries.

[9]  A. Boyle,et al.  COVID-19: resetting ED care , 2020, Emergency Medicine Journal.

[10]  M. Extermann,et al.  Older patients with cancer and febrile neutropenia in the COVID-19 era: A new concern , 2020, Journal of Geriatric Oncology.

[11]  M. Taljaard,et al.  Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis. , 2020, Critical reviews in oncology/hematology.

[12]  Yu-Ching Lin,et al.  The Association Between Emergency Department Revisit and Elderly Patients. , 2020, Journal of acute medicine.

[13]  B. Nathanson,et al.  Abnormal shock index exposure and clinical outcomes among critically ill patients: A retrospective cohort analysis. , 2020, Journal of critical care.

[14]  D. Talan,et al.  Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: Is there room for improvement? , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[15]  F. Shih,et al.  Emergency department revisits: a nation-wide database analysis on the same and different hospital revisits , 2019, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[16]  P. Aggarwal,et al.  CISNE versus MASCC: Identifying low risk febrile neutropenic patients. , 2019, The American journal of emergency medicine.

[17]  D. Sciubba,et al.  Lactate and cancer: a "lactatic" perspective on spinal tumor metabolism (part 1). , 2019, Annals of translational medicine.

[18]  C. Camargo,et al.  Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia , 2019, PloS one.

[19]  G. Soff,et al.  Management of Thrombocytopenia in Cancer Patients. , 2019, Cancer treatment and research.

[20]  S. Sim,et al.  Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment? , 2018, PloS one.

[21]  K. Jeffers,et al.  Assessment of Initial Febrile Neutropenia Management in Hospitalized Cancer Patients at a Community Cancer Center , 2018, Journal of the advanced practitioner in oncology.

[22]  M. Salavert,et al.  Management of Infection and Febrile Neutropenia in Patients with Solid Cancer. , 2017, Enfermedades infecciosas y microbiologia clinica.

[23]  J. Karp,et al.  Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. , 2017, Cancer biomarkers : section A of Disease markers.

[24]  Karen L. Ferran,et al.  Application of the MASCC and CISNE Risk‐Stratification Scores to Identify Low‐Risk Febrile Neutropenic Patients in the Emergency Department , 2017, Annals of emergency medicine.

[25]  Thomas J. Wang,et al.  Emergency Department Management of Patients With Febrile Neutropenia: Guideline Concordant or Overly Aggressive? , 2017, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[26]  Jinoos Yazdany,et al.  Revisit Rates and Associated Costs After an Emergency Department Encounter , 2015, Annals of Internal Medicine.

[27]  M. Mamtani,et al.  Can we safely discharge low-risk patients with febrile neutropenia from the emergency department? , 2014, Annals of emergency medicine.

[28]  Y. Weng,et al.  Risk factors associated with complications in patients with chemotherapy‐induced febrile neutropenia in emergency department , 2013, Hematological oncology.

[29]  Franziska Hirschhaeuser,et al.  Lactate: a metabolic key player in cancer. , 2011, Cancer research.

[30]  E. Gonzalez-Billalabeitia,et al.  Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients , 2011, British Journal of Cancer.

[31]  Kyung Soo Lim,et al.  Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia , 2011, Supportive Care in Cancer.

[32]  N. Cherny.  Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. , 2008, Journal of Pain and Symptom Management.

[33]  B. Murphy.  Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. , 2007, The journal of supportive oncology.

[34]  T. Gaeta,et al.  Shock index in diagnosing early acute hypovolemia. , 2005, The American journal of emergency medicine.

[35]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Hassan,et al.  Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it. , 1996, Journal of hematotherapy.

[37]  R. Kreisberg.  Lactate homeostasis and lactic acidosis. , 1980, Annals of internal medicine.